Zerbaxa is a medication applied across domains where additional symptomatic support is needed for serious, specific bacterial infections. The medication is relevant in clinical settings marked by heightened systemic burden, in three main therapeutic areas: complicated urinary tract infections (cUTI), complicated intra-abdominal infections (cIAI), and specific types of pneumonia (HABP/VABP).

Management of Complicated Infections and Symptom Patterns

This medication is used in situations involving certain distressing symptoms linked to these conditions. It helps address symptom clusters that may become intense or disruptive and is commonly used across conditions presenting with acute episodes.

“Zerbaxa may support patients during difficult episodes by assisting with symptomatic management when symptoms become temporarily overwhelming.”

It is applied in scenarios where additional management of discomfort is required, contributing to easing the overall symptom load and supporting general well-being during symptomatic phases.

• Quick Fact: Relief for Heightened Discomfort Zerbaxa is applied in situations where patients experience heightened discomfort and need short-term symptomatic assistance.

Regulatory References

1. European Medicines Agency overview

Eligibility Scope

Contraindications and Conditional Use

• Populations for whom use is contraindicated: Zerbaxa is prohibited for patients with a known serious hypersensitivity (allergy) to its active components (ceftolozane/tazobactam), any cephalosporin antibacterial agent, or any severe allergic reaction to other beta-lactam class antibiotics (such as penicillins).
• Conditional Use (Renal Status): Eligibility is conditional on kidney function. Adult patients with moderate or severe renal impairment or End-Stage Renal Disease are eligible, but the official label mandates a dose adjustment. Use is not recommended for pediatric patients with significantly impaired renal function (eGFR le 50 mL/min/1.73 m^2) due to insufficient regulatory data.
• Pregnancy/Lactation: Use during pregnancy is permitted only if the potential benefit justifies the risk to the fetus. Data on drug presence in human milk are absent, necessitating caution during lactation.

The official interaction profile for Zerbaxa (Ceftolozane/Tazobactam) is structured around its non-metabolic, renal clearance pathway. The active components are not significantly metabolized by the Cytochrome P450 (CYP) enzyme system, which simplifies the drug-drug interaction landscape and results in no documented clinically significant interactions with common CYP substrates, inhibitors, or inducers. Interactions are primarily focused on drug clearance, physical compatibility, and specific pre-existing conditions.

Interaction notes also detail that exposure of both Ceftolozane and Tazobactam is significantly increased in patients with renal impairment. This population-specific pharmacokinetic finding is a direct result of the drug's primary elimination via the kidneys. Regulatory documents do not contain specific statements about interactions with food, alcohol, or herbal products. The overall interaction structure is defined by its minimal reliance on hepatic metabolism and its dominant renal clearance mechanism.

The mechanism of Ceftolozane/Tazobactam is a dual-action process targeting bacterial structural synthesis and enzymatic defense. Ceftolozane, the cephalosporin component, acts as a covalent inhibitor of essential Penicillin-Binding Proteins (PBPs). Specifically, it binds to and inactivates PBPs responsible for the transpeptidation reaction, arresting the final stage of peptidoglycan cross-linking necessary for bacterial cell wall rigidity. This structural compromise initiates a cascade that leads to a profound change in the bacterial cell's osmotic state. Tazobactam provides crucial synergy by functioning as an irreversible inhibitor of certain Ambler Class A beta-lactamase enzymes, including Extended-Spectrum Beta-Lactamases (ESBLs). By neutralizing these bacterial defenses, Tazobactam ensures that intact Ceftolozane reaches its PBP targets in sufficient concentration to complete the inhibitory mechanism. This coordinated action results in the physiological consequence of bacterial cell lysis. The mechanism does not extend to organisms that produce Metallo-beta-lactamases (MBLs) due to the specificity of Tazobactam's inhibitory profile.

Zerbaxa (Ceftolozane/Tazobactam) is administered strictly as an intravenous infusion within a supervised clinical environment. The medicine is supplied as a sterile powder in single-dose vials that must be reconstituted and diluted before use; the reconstituted solution is not for direct injection. All doses are administered over a 1-hour period every 8 hours (q8h).

Official Labeled Dosing Regimens

Dosage is determined by the specific type of infection and the patient's kidney function (Creatinine Clearance, CrCl). No adjustment is required based on age alone for older adults.

For cIAI, Zerbaxa must be used concurrently with metronidazole to provide comprehensive antimicrobial coverage.

Population-Specific Use and Adjustments

Renal Impairment: Dose adjustment is mandatory for adult patients with a CrCl of 50 mL/min or less. The dosage is reduced incrementally based on the severity of renal impairment to ensure appropriate systemic exposure. Creatinine Clearance must be monitored regularly in patients with changing renal function, and the dosage adjusted accordingly.

Pediatric Use: For complicated intra-abdominal and urinary tract infections in pediatric patients (birth to <18 years), the dose is calculated based on body weight, up to a maximum of 1.5 g per dose, administered every 8 hours. Zerbaxa is not recommended for pediatric patients with an estimated GFR of 50 mL/min/1.73 m^2 or less.

Zerbaxa (Ceftolozane/Tazobactam): Recent Clinical Evidence

Clinical research has evaluated the combination antibiotic ceftolozane/tazobactam (marketed as Zerbaxa) across several key infectious disease indications. This drug combination is a cephalosporin antibacterial agent combined with a beta-lactamase inhibitor, and its development focused on addressing serious infections caused by Gram-negative bacteria, including multidrug-resistant strains.

Indications and Key Trials

Research studies have examined the use of ceftolozane/tazobactam in the treatment of specific complicated bacterial infections:

• Complicated Intra-abdominal Infections (cIAIs): Studies, often involving comparison against meropenem, have evaluated whether the combination was associated with clinical success rates in adult participants with cIAIs, typically in combination with metronidazole.
• Complicated Urinary Tract Infections (cUTIs): Trials, including those for pyelonephritis, evaluated the drug combination against a control group (such as levofloxacin). Researchers assessed the microbiological and clinical response in participants with cUTIs.
• Hospital-acquired Bacterial Pneumonia (HABP) and Ventilator-associated Bacterial Pneumonia (VABP): Large-scale trials have been conducted to evaluate the efficacy and safety of ceftolozane/tazobactam in treating adults with HABP/VABP, particularly focusing on strains resistant to other common antimicrobials.

Safety and Resistance

Safety profiles have been evaluated across these studies, documenting the frequency of adverse events. Research emphasizes the drug's activity against difficult-to-treat pathogens, including Pseudomonas aeruginosa and some Extended-Spectrum Beta-Lactamase (ESBL)-producing Enterobacteriaceae strains. Continued surveillance of clinical outcomes and resistance patterns is ongoing to guide appropriate use.

Key Studies & References

1. Ceftolozane–Tazobactam versus Levofloxacin for the Treatment of Complicated Urinary Tract Infections in Hospitalized Adults: Results of a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cUTI)
2. Efficacy and Safety of Ceftolozane–Tazobactam versus Meropenem in Ventilated Nosocomial Pneumonia (ASPECT-NP): A Randomized, Controlled Trial

Common questions about Zerbaxa (CEFTOLOZANE) (FAQ)

Q: What is Zerbaxa used for?

Zerbaxa (ceftolozane and tazobactam) is indicated for treating specific bacterial infections. These typically include certain complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI). It is also used to treat certain hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP).

Q: How does Zerbaxa differ from other antibiotics?

Zerbaxa is a combination of two medications: ceftolozane, a cephalosporin antibiotic, and tazobactam, a beta-lactamase inhibitor. This combination is designed to fight specific Gram-negative bacteria that may be resistant to other types of antibiotics. The tazobactam component helps ceftolozane remain active against bacteria that produce certain enzymes which would otherwise inactivate the antibiotic.

Q: How is Zerbaxa administered?

Zerbaxa is administered intravenously, meaning it is given directly into a vein. It is typically given as an infusion over a fixed period. The exact dose and frequency are determined by a healthcare provider based on the type and severity of the infection, and the patient's kidney function.

Q: What are some potential side effects of Zerbaxa?

Reported side effects can vary. Common reactions observed in clinical trials include nausea, headache, diarrhea, and fever. More serious, but less common, effects can include hypersensitivity reactions, such as severe allergic responses, and Clostridioides difficile-associated diarrhea (CDAD). Patients are encouraged to discuss any concerns about side effects with their healthcare provider.

Q: Can Zerbaxa be used during pregnancy or breastfeeding?

Limited data are available regarding the use of Zerbaxa during pregnancy and breastfeeding. The decision to use this medication in these situations requires careful consideration by a healthcare provider, weighing the potential benefits against any possible risks to the mother and fetus or infant. Patients who are pregnant, planning to become pregnant, or breastfeeding should inform their provider before receiving Zerbaxa.

Q: Is Zerbaxa effective against all types of bacterial infections?

No. Zerbaxa is a targeted antibiotic and is only effective against susceptible bacteria as determined by laboratory testing. It is not active against viral infections, such as the common cold or flu. It is used specifically for the complex infections for which it is indicated, as its spectrum of activity is limited to certain strains of Gram-negative bacteria.

How to Store and Dispose of ZERBAXA (Ceftolozane/Tazobactam)

The official storage requirements for ZERBAXA, a sterile powder for injection, mandate strict temperature control and protection from light to maintain stability.

Storage Requirements

The unreconstituted powder vials must be stored in a refrigerator at 2 C to 8 C (36 F to 46 F). The vials must remain in the original package to protect from light.

All solutions must not be frozen. The medicine must be kept out of the sight and reach of children.

Disposal

Any unused portion of the prepared solution must be discarded. Disposal of the unused product and related materials must be carried out in accordance with local requirements for pharmaceutical waste, as regulatory assessments indicate a potential risk to surface water organisms.